Report Detail
Covid-19 Impact on Biopharmaceutical Cmo & Cro Market, Global Research Reports 2020-2021
- RnM3972299 |
- 18 May, 2020 |
- Global |
- 106 Pages |
- QYResearch |
- Chemical & Material
This report covers market size and forecasts of Biopharmaceutical Cmo & Cro, including the following market information:
Global Biopharmaceutical Cmo & Cro Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Biopharmaceutical Cmo & Cro Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Biopharmaceutical Cmo & Cro Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million) & (K MT)
Global Biopharmaceutical Cmo & Cro Market Size by Company, 2019- 2020 (quarterly data), (US$ Million) & (K MT)
Key market players
Major competitors identified in this market include Lonza, Boehringer Ingelheim GmbH, Rentschler Biotechnologie GmbH, Inno Biologics Sdn Bhd, JRS Pharma (Celonic GmbH), BIOMEVA GmbH, ProBioGen, FUJIFILM Diosynth Biotechnologies U.S.A., Inc., TOYOBO CO., LTD, Samsung BioLogics, Patheon, CMC Biologics, Binex Co., Ltd., AbbVie Inc., WuXi Biologics., etc.
Based on the Region:
Asia-Pacific (China, Japan, South Korea, India and ASEAN)
North America (US and Canada)
Europe (Germany, France, UK and Italy)
Rest of World (Latin America, Middle East & Africa)
Based on the Type:
Biologics
Biosimilars
Based on the Application:
Contract Manufacturing
Contract Research
- 1.4.1 Research Process
- 1.4.2 Data Triangulation
- 1.4.3 Research Approach
- 1.4.4 Base Year
- 1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
- 1.5.2 Covid-19 Impact: Commodity Prices Indices
- 1.5.3 Covid-19 Impact: Global Major Government Policy
2 Global Biopharmaceutical Cmo & Cro Quarterly Market Size Analysis
- 2.1 Biopharmaceutical Cmo & Cro Business Impact Assessment - COVID-19
- 2.1.1 Global Biopharmaceutical Cmo & Cro Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.1.2 Global Biopharmaceutical Cmo & Cro Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026
- 2.2 Global Biopharmaceutical Cmo & Cro Quarterly Market Size 2020-2021
- 2.3 COVID-19-Driven Market Dynamics and Factor Analysis
- 2.3.1 Drivers
- 2.3.2 Restraints
- 2.3.3 Opportunities
- 2.3.4 Challenges
3 Quarterly Competitive Assessment, 2020
- 3.1 Global Biopharmaceutical Cmo & Cro Quarterly Market Size by Manufacturers, 2019 VS 2020
- 3.2 Global Biopharmaceutical Cmo & Cro Factory Price by Manufacturers
- 3.3 Location of Key Manufacturers Biopharmaceutical Cmo & Cro Manufacturing Factories and Area Served
- 3.4 Date of Key Manufacturers Enter into Biopharmaceutical Cmo & Cro Market
- 3.5 Key Manufacturers Biopharmaceutical Cmo & Cro Product Offered
- 3.6 Mergers & Acquisitions, Expansion Plans
4 Impact of Covid-19 on Biopharmaceutical Cmo & Cro Segments, By Type
- 4.1 Introduction
- 1.4.1 Biologics
- 1.4.2 Biosimilars
- 4.2 By Type, Global Biopharmaceutical Cmo & Cro Market Size, 2019-2021
- 4.2.1 By Type, Global Biopharmaceutical Cmo & Cro Market Size by Type, 2020-2021
- 4.2.2 By Type, Global Biopharmaceutical Cmo & Cro Price, 2020-2021
5 Impact of Covid-19 on Biopharmaceutical Cmo & Cro Segments, By Application
- 5.1 Overview
- 5.5.1 Contract Manufacturing
- 5.5.2 Contract Research
- 5.2 By Application, Global Biopharmaceutical Cmo & Cro Market Size, 2019-2021
- 5.2.1 By Application, Global Biopharmaceutical Cmo & Cro Market Size by Application, 2019-2021
- 5.2.2 By Application, Global Biopharmaceutical Cmo & Cro Price, 2020-2021
6 Geographic Analysis
- 6.1 Introduction
- 6.2 North America
- 6.2.1 Macroeconomic Indicators of US
- 6.2.2 US
- 6.2.3 Canada
- 6.3 Europe
- 6.3.1 Macroeconomic Indicators of Europe
- 6.3.2 Germany
- 6.3.3 France
- 6.3.4 UK
- 6.3.5 Italy
- 6.4 Asia-Pacific
- 6.4.1 Macroeconomic Indicators of Asia-Pacific
- 6.4.2 China
- 6.4.3 Japan
- 6.4.4 South Korea
- 6.4.5 India
- 6.4.6 ASEAN
- 6.5 Rest of World
- 6.5.1 Latin America
- 6.5.2 Middle East and Africa
7 Company Profiles
- 7.1 Lonza
- 7.1.1 Lonza Business Overview
- 7.1.2 Lonza Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.1.3 Lonza Biopharmaceutical Cmo & Cro Product Introduction
- 7.1.4 Lonza Response to COVID-19 and Related Developments
- 7.2 Boehringer Ingelheim GmbH
- 7.2.1 Boehringer Ingelheim GmbH Business Overview
- 7.2.2 Boehringer Ingelheim GmbH Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.2.3 Boehringer Ingelheim GmbH Biopharmaceutical Cmo & Cro Product Introduction
- 7.2.4 Boehringer Ingelheim GmbH Response to COVID-19 and Related Developments
- 7.3 Rentschler Biotechnologie GmbH
- 7.3.1 Rentschler Biotechnologie GmbH Business Overview
- 7.3.2 Rentschler Biotechnologie GmbH Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.3.3 Rentschler Biotechnologie GmbH Biopharmaceutical Cmo & Cro Product Introduction
- 7.3.4 Rentschler Biotechnologie GmbH Response to COVID-19 and Related Developments
- 7.4 Inno Biologics Sdn Bhd
- 7.4.1 Inno Biologics Sdn Bhd Business Overview
- 7.4.2 Inno Biologics Sdn Bhd Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.4.3 Inno Biologics Sdn Bhd Biopharmaceutical Cmo & Cro Product Introduction
- 7.4.4 Inno Biologics Sdn Bhd Response to COVID-19 and Related Developments
- 7.5 JRS Pharma (Celonic GmbH)
- 7.5.1 JRS Pharma (Celonic GmbH) Business Overview
- 7.5.2 JRS Pharma (Celonic GmbH) Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.5.3 JRS Pharma (Celonic GmbH) Biopharmaceutical Cmo & Cro Product Introduction
- 7.5.4 JRS Pharma (Celonic GmbH) Response to COVID-19 and Related Developments
- 7.6 BIOMEVA GmbH
- 7.6.1 BIOMEVA GmbH Business Overview
- 7.6.2 BIOMEVA GmbH Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.6.3 BIOMEVA GmbH Biopharmaceutical Cmo & Cro Product Introduction
- 7.6.4 BIOMEVA GmbH Response to COVID-19 and Related Developments
- 7.7 ProBioGen
- 7.7.1 ProBioGen Business Overview
- 7.7.2 ProBioGen Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.7.3 ProBioGen Biopharmaceutical Cmo & Cro Product Introduction
- 7.7.4 ProBioGen Response to COVID-19 and Related Developments
- 7.8 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- 7.8.1 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Business Overview
- 7.8.2 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.8.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Biopharmaceutical Cmo & Cro Product Introduction
- 7.8.4 FUJIFILM Diosynth Biotechnologies U.S.A., Inc. Response to COVID-19 and Related Developments
- 7.9 TOYOBO CO., LTD
- 7.9.1 TOYOBO CO., LTD Business Overview
- 7.9.2 TOYOBO CO., LTD Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.9.3 TOYOBO CO., LTD Biopharmaceutical Cmo & Cro Product Introduction
- 7.9.4 TOYOBO CO., LTD Response to COVID-19 and Related Developments
- 7.10 Samsung BioLogics
- 7.10.1 Samsung BioLogics Business Overview
- 7.10.2 Samsung BioLogics Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.10.3 Samsung BioLogics Biopharmaceutical Cmo & Cro Product Introduction
- 7.10.4 Samsung BioLogics Response to COVID-19 and Related Developments
- 7.11 Patheon
- 7.11.1 Patheon Business Overview
- 7.11.2 Patheon Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.11.3 Patheon Biopharmaceutical Cmo & Cro Product Introduction
- 7.11.4 Patheon Response to COVID-19 and Related Developments
- 7.12 CMC Biologics
- 7.12.1 CMC Biologics Business Overview
- 7.12.2 CMC Biologics Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.12.3 CMC Biologics Biopharmaceutical Cmo & Cro Product Introduction
- 7.12.4 CMC Biologics Response to COVID-19 and Related Developments
- 7.13 Binex Co., Ltd.
- 7.13.1 Binex Co., Ltd. Business Overview
- 7.13.2 Binex Co., Ltd. Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.13.3 Binex Co., Ltd. Biopharmaceutical Cmo & Cro Product Introduction
- 7.13.4 Binex Co., Ltd. Response to COVID-19 and Related Developments
- 7.14 AbbVie Inc.
- 7.14.1 AbbVie Inc. Business Overview
- 7.14.2 AbbVie Inc. Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.14.3 AbbVie Inc. Biopharmaceutical Cmo & Cro Product Introduction
- 7.14.4 AbbVie Inc. Response to COVID-19 and Related Developments
- 7.15 WuXi Biologics.
- 7.15.1 WuXi Biologics. Business Overview
- 7.15.2 WuXi Biologics. Biopharmaceutical Cmo & Cro Quarterly Production and Revenue, 2020
- 7.15.3 WuXi Biologics. Biopharmaceutical Cmo & Cro Product Introduction
- 7.15.4 WuXi Biologics. Response to COVID-19 and Related Developments
8 Supply Chain and Sales Channels Analysis
- 8.1 Biopharmaceutical Cmo & Cro Supply Chain Analysis
- 8.1.1 Biopharmaceutical Cmo & Cro Supply Chain Analysis
- 8.1.2 Covid-19 Impact on Biopharmaceutical Cmo & Cro Supply Chain
- 8.2 Distribution Channels Analysis
- 8.2.1 Biopharmaceutical Cmo & Cro Distribution Channels
- 8.2.2 Covid-19 Impact on Biopharmaceutical Cmo & Cro Distribution Channels
- 8.2.3 Biopharmaceutical Cmo & Cro Distributors
- 8.3 Biopharmaceutical Cmo & Cro Customers
9 Key Findings
10 Appendix
- 10.1 About Us
Summary:
Get latest Market Research Reports on Covid-19 Impact on Biopharmaceutical Cmo & Cro. Industry analysis & Market Report on Covid-19 Impact on Biopharmaceutical Cmo & Cro is a syndicated market report, published as Covid-19 Impact on Biopharmaceutical Cmo & Cro Market, Global Research Reports 2020-2021. It is complete Research Study and Industry Analysis of Covid-19 Impact on Biopharmaceutical Cmo & Cro market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
